Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study
(2022) Chest : the cardiopulmonary and critical care journal — Vol. 162, n° 1, p. 76-81 (2022)
Files
ALISMabscNTMNETmanuscript15-07-2021002-abstract.docx
Open Access - Microsoft Word XML
- 23.7 KB
Details
- Authors
- Abstract
- (en) TO THE EDITOR : Mycobacterium abscessus is an opportunistic pathogen notorious for its antibiotic resistance and poor treatment outcomes.1 Treatment regimens for M abscessus pulmonary disease consist of an intensive phase of 2 to 3 months of IV antibiotics (including amikacin, imipenem or cefoxitin, and tigecycline) combined with oral drugs (including clofazimine, linezolid, azithromycin). The continuation phase consists of two or three oral antibiotics, preferably with proven in vitro activity, and inhaled amikacin. [...]
- Affiliations
Citations
Zweijpfenning Sanne, Chiron, r., Essink, S., Schildkraut, J., Akkerman, O., Aliberti, S., Altenburg, J., Arets, H., Van Braeckel, E., Delaere, B., Gohy, S., Haarman, E., Lorent, N., McKew, G., Morgan, L., Wagner, D., van Ingen, J., & Hoefsloot, W. (2022). Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study. Chest : the cardiopulmonary and critical care journal, 162(1), 76-81. https://doi.org/10.1016/j.chest.2022.01.015 (Original work published 2022)